Medical News

[ Behavioral Treatment For Migraines A Cost-Effective Alternative To Meds ]

Behavioral Treatment For Migraines A Cost-Effective Alternative To Meds

Treating chronic migraines with behavioral approaches - such as relaxation training, hypnosis and biofeedback - can make financial sense compared to prescription-drug treatment, especially after a year or more, a new study found. Longtime behavioral therapy researcher and practitioner Dr. Donald Penzien, University of Mississippi Medical Center professor of psychiatry, coauthored the study. He said the costs of prescription prophylactic drugs - the kind chronic migraine sufferers take every day to prevent onset - may not seem much even at several dollars a day. "But those costs keep adding up with additional doctor visits and more prescriptions, " Penzien said. "The cost of behavioral treatment is front-loaded. You go to a number of treatment sessions but then that's it. And the benefits last for years.

Common Forms Of Neck Pain Not Cured By Botulinum Toxin

There is no evidence that Botulinum toxin injections reduce chronic neck pain or associated headaches, says a group of scientists who reviewed nine trials involving a total of 503 participants. Their findings are published in the latest update of The Cochrane Library. The Botulinum toxin (BoNT) operates by temporarily stopping muscles contracting. This reduces muscle tightness or spasm. It is best known for its use in cosmetic treatments where commercially available products such as Botox, Dysport, Xeomin, Myobloc or Neurobloc are used to reduce wrinkles. Effects begin within three to eight days of an injection and may last up to four months. When the effect wears off, it can be repeated. Having an injection of a very small volume of BoNT is not risk free, and patients may experience muscle tenderness or pain, weakness, or a general sense of being unwell.

Autonomic Technologies Announces Positive Preliminary Findings For A Novel Device For The Treatment Of Severe Headache

Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable system for severe headaches, today announced positive preliminary findings from a study evaluating the safety and efficacy of the company's investigational neurostimulation system for the treatment of cluster headache. Jean Schoenen, M.D., coordinator of the Headache Research Unit at University of Liege in Liege, Belgium, presented the findings at a late breaking session today at the 15th Congress of the International Headache Society in Berlin, Germany. Cluster headache is a highly disabling neurologic condition characterized by intense stabbing pain in the area of one eye, often accompanied by swelling, tears and nasal congestion. Often called 'suicide headache, ' the pain inflicted by the condition is recognized as amongst the most severe known to man.

Evidence of Increased Health Risks From Volcanic Air Pollution

Kilauea Volcano on Hawaii's big island has been erupting on its east rift since 1983. But, in March 2008, an additional eruption vent opened at the volcano's summit, resulting in about triple the amount of sulfur dioxide gas (SO2) emissions drifting to the local community of Ka'u, raising health concerns over the risks associated with exposure to "vog, " as the islanders refer to this volcanic air pollution. A University of Nevada, Reno researcher seized the opportunity to build upon her previous research of health risks associated with exposure to vog. Bernadette Longo, assistant professor at the University's Orvis School of Nursing, embarked on a study to compare local health clinic records for the 14 weeks prior to the March 2008 eruption on the summit, to the health clinic records March through June 2008, when the volcano's SO2 emissions tripled.

MAP Pharmaceuticals To Present Data Showing Low Migraine Recurrence Rates With LEVADEX trade; In FREEDOM-301 Trial

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced new data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy showing low recurrence rates with LEVADEX. Eight additional analyses from the LEVADEX program also will be presented during the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France. Physicians commonly use the term recurrence to assess the sustained action of a migraine drug. However, there is not a standard definition of recurrence, and different methods are used in the clinical setting to calculate recurrence rates. This analysis calculated recurrence rates using four different definitions from the literature to illustrate the variability of using this endpoint for comparing different migraine treatments.

Fast: [10]

Medical News © Nanda
Designer Damodar